Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
